Retour

VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action

News Verve Therapeutics

Verve Therapeutics, Inc. is facing a class action lawsuit alleging that the company misled investors about the circumstances under which its Heart-1 clinical trial would be halted and overstated the potential benefits of its proprietary LNP delivery system.

GlobeNewswire Inc. • 05/09/2024 à 00:36:00
Verve Therapeutics, Inc. Common Stock
Adresse: 201 BROOKLINE AVENUE
Code postal: 02215
Ville: BOSTON
Region: MA
Numéro de telephone: (978) 501-3026
Site internet: https://www.vervetx.com
Status: Active
Info de l'entreprise

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Date de référencement2021-06-17
MarchéStocks
LocaleUS
Echange principalXNAS
TypeCS
DeviseUSD
CIK0001840574
Composite figiBBG00P33TCZ8
Share Class figiBBG00P33TD13
Market Cap473,474,240 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employés255
Share Class Shares Outstanding84630000
Weighted Shares Outstanding84624529
Round Lot100
Date de mise à jour2024-09-07
Stats
Historique
PériodeVarPlus hautPlus bas
1 semaine
-17.07%
6.774
5.711
1 mois
-3.91%
5.824
4.671
3 mois
9.59%
5.37
4.671
6 mois
-63.85%
16.03
4.671
1 an
-56.11%
12.87
4.671
3 ans
-92.16%
71.87
4.671
5 ans
-81.48%
33.96
4.671
10 ans
-81.48%
33.96
4.671
Actions
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-10 2023-11-07 UNPUB
Assets 634,376,000 589,131,000 612,407,000 UNPUB
Current Assets 517,787,000 473,066,000 498,261,000 UNPUB
Current Liabilities 33,552,000 33,031,000 34,575,000 UNPUB
Equity 509,476,000 465,222,000 460,369,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 509,476,000 465,222,000 460,369,000 UNPUB
Liabilities 124,900,000 123,909,000 152,038,000 UNPUB
Liabilities And Equity 634,376,000 589,131,000 612,407,000 UNPUB
Noncurrent Assets 116,589,000 116,065,000 114,146,000 UNPUB
Noncurrent Liabilities 91,348,000 90,878,000 117,463,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-10 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -31,666,000 -13,704,000 8,278,000 UNPUB
Net Cash Flow, Continuing -31,666,000 -13,704,000 8,278,000 UNPUB
Net Cash Flow From Financing Activities 2,038,000 1,233,000 31,923,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 2,038,000 1,233,000 31,923,000 UNPUB
Net Cash Flow From Investing Activities 15,392,000 33,025,000 -11,834,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 15,392,000 33,025,000 -11,834,000 UNPUB
Net Cash Flow From Operating Activities -49,096,000 -47,962,000 -11,811,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -49,096,000 -47,962,000 -11,811,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-10 2023-11-07 UNPUB
Comprehensive Income/Loss -51,518,000 -54,500,000 -45,601,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -51,518,000 -54,500,000 -45,601,000 UNPUB
Other Comprehensive Income/Loss 457,000 -54,500,000 -45,601,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent 457,000 -517,000 157,000 UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-15 2023-08-10 2023-11-07 UNPUB
Basic Earnings Per Share -1 -1 -1 UNPUB
Benefits Costs and Expenses 53,379,000 55,900,000 48,808,000 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 59,663,000 60,676,000 55,451,000 UNPUB
Diluted Earnings Per Share -1 -1 -1 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -51,975,000 -53,983,000 -45,758,000 UNPUB
Income/Loss From Continuing Operations Before Tax -51,975,000 -53,807,000 -45,691,000 UNPUB
Income Tax Expense/Benefit UNPUB 176,000 67,000 UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -51,975,000 -53,983,000 -45,758,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -51,975,000 -53,983,000 -45,758,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -51,975,000 -53,983,000 -45,758,000 UNPUB
Operating Expenses 59,663,000 60,676,000 55,451,000 UNPUB
Operating Income/Loss -58,259,000 -58,583,000 -52,334,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 1,404,000 2,093,000 3,117,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-07 2023-03-02
Assets 349,241,000 324,267,000 673,355,000 679,223,000
Current Assets 328,830,000 298,644,000 561,630,000 563,159,000
Current Liabilities 14,803,000 25,847,000 29,018,000 35,095,000
Equity 331,390,000 296,333,000 547,943,000 550,932,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 331,390,000 296,333,000 547,943,000 550,932,000
Liabilities 17,851,000 27,934,000 125,412,000 128,291,000
Liabilities And Equity 349,241,000 324,267,000 673,355,000 679,223,000
Noncurrent Assets 20,411,000 25,623,000 111,725,000 116,064,000
Noncurrent Liabilities 0 0 96,394,000 93,196,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-07 2023-03-02
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 27,090,000 -18,531,000 203,717,000 50,669,000
Net Cash Flow, Continuing 27,090,000 -18,531,000 203,717,000 50,669,000
Net Cash Flow From Financing Activities 505,000 445,000 288,408,000 328,956,000
Net Cash Flow From Financing Activities, Continuing 505,000 445,000 288,408,000 328,956,000
Net Cash Flow From Investing Activities 60,092,000 7,782,000 -55,516,000 -155,955,000
Net Cash Flow From Investing Activities, Continuing 60,092,000 7,782,000 -55,516,000 -155,955,000
Net Cash Flow From Operating Activities -33,507,000 -26,758,000 -29,175,000 -122,332,000
Net Cash Flow From Operating Activities, Continuing -33,507,000 -26,758,000 -29,175,000 -122,332,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-07 2023-03-02
Comprehensive Income/Loss -30,166,000 -40,946,000 -45,172,000 -157,853,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -30,670,000 -41,152,000 -45,172,000 -157,853,000
Other Comprehensive Income/Loss 0 0 -45,172,000 -466,000
Other Comprehensive Income/Loss Attributable To Parent -504,000 -206,000 18,000 -466,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-09 2022-11-07 2023-03-02
Basic Earnings Per Share UNPUB UNPUB -1 -3
Benefits Costs and Expenses UNPUB UNPUB 46,119,000 159,275,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 44,789,000 167,628,000
Diluted Earnings Per Share UNPUB UNPUB -1 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -30,166,000 -40,946,000 -45,190,000 -157,387,000
Income/Loss From Continuing Operations Before Tax -30,166,000 -40,946,000 -45,190,000 -157,334,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 53,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -30,166,000 -40,946,000 -45,190,000 -157,387,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -30,166,000 -40,946,000 -45,190,000 -157,387,000
Net Income/Loss Available To Common Stockholders, Basic -30,166,000 -40,946,000 -45,190,000 -157,387,000
Operating Expenses 31,925,000 42,192,000 44,789,000 167,628,000
Operating Income/Loss -31,925,000 -42,192,000 -43,860,000 -165,687,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 929,000 1,941,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-14
Assets UNPUB UNPUB 410,877,000 384,124,000
Current Assets UNPUB UNPUB 394,437,000 367,128,000
Current Liabilities UNPUB UNPUB 20,251,000 22,024,000
Equity UNPUB UNPUB 384,935,000 357,352,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 384,935,000 357,352,000
Liabilities UNPUB UNPUB 25,942,000 26,772,000
Liabilities And Equity UNPUB UNPUB 410,877,000 384,124,000
Noncurrent Assets UNPUB UNPUB 16,440,000 16,996,000
Noncurrent Liabilities UNPUB UNPUB 5,691,000 4,748,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-14
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB UNPUB 60,111,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 60,111,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 377,089,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 377,089,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -239,098,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -239,098,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -77,880,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -77,880,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-14
Comprehensive Income/Loss UNPUB UNPUB -22,754,000 -120,550,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -22,754,000 -120,550,000
Other Comprehensive Income/Loss UNPUB UNPUB -22,754,000 -236,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -5,000 -236,000
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-10 2022-03-14
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -22,749,000 -120,314,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -22,749,000 -120,314,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -22,749,000 -120,314,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -22,749,000 -120,314,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -22,749,000 -120,314,000
Operating Expenses UNPUB UNPUB 23,502,000 87,067,000
Operating Income/Loss UNPUB UNPUB -23,502,000 -87,067,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 0 0
Calendrier économique
6 Septembre 2024 (heure UTC) Actuel Précédent Consensus
★
15:30
United States
SEP 03
-27700.000
-32700.000
★
15:30
United States
SEP 03
46100.000
52200.000
★
15:30
United States
SEP 03
-48800.000
-81900.000
★
15:30
United States
SEP 03
-100300.000
-92200.000
★★
15:30
United States
SEP 03
26000.000
21400.000
★
15:30
United States
SEP 03
287600.000
294400.000
★
15:30
United States
SEP 03
177000.000
226700.000
★
15:30
United States
SEP 03
-90500.000
-148500.000
★
15:30
United States
SEP 03
-162000.000
-184300.000
★
15:30
United States
SEP 03
13000.000
17100.000
★
15:30
United States
SEP 03
2300.000
2200.000
★
15:30
United States
★
15:30
United States
★★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:VERV240816P00035000 OPASPS Put American 100 35 BATO 2024-08-16
O:VERV240816P00030000 OPASPS Put American 100 30 BATO 2024-08-16
O:VERV240816C00035000 OCASPS Call American 100 35 BATO 2024-08-16
O:VERV240816C00030000 OCASPS Call American 100 30 BATO 2024-08-16
O:VERV240816P00025000 OPASPS Put American 100 25 BATO 2024-08-16
O:VERV240816P00022500 OPASPS Put American 100 22.5 BATO 2024-08-16
O:VERV240816P00020000 OPASPS Put American 100 20 BATO 2024-08-16
O:VERV240816P00017500 OPASPS Put American 100 17.5 BATO 2024-08-16
O:VERV240816P00015000 OPASPS Put American 100 15 BATO 2024-08-16
O:VERV240816P00012500 OPASPS Put American 100 12.5 BATO 2024-08-16
O:VERV240816P00010000 OPASPS Put American 100 10 BATO 2024-08-16
O:VERV240816P00007500 OPASPS Put American 100 7.5 BATO 2024-08-16
O:VERV240816P00005000 OPASPS Put American 100 5 BATO 2024-08-16
O:VERV240816P00002500 OPASPS Put American 100 2.5 BATO 2024-08-16
O:VERV240816C00025000 OCASPS Call American 100 25 BATO 2024-08-16
O:VERV240816C00022500 OCASPS Call American 100 22.5 BATO 2024-08-16
O:VERV240816C00020000 OCASPS Call American 100 20 BATO 2024-08-16
O:VERV240816C00017500 OCASPS Call American 100 17.5 BATO 2024-08-16
O:VERV240816C00015000 OCASPS Call American 100 15 BATO 2024-08-16
O:VERV240816C00012500 OCASPS Call American 100 12.5 BATO 2024-08-16
O:VERV240816C00010000 OCASPS Call American 100 10 BATO 2024-08-16
O:VERV240816C00007500 OCASPS Call American 100 7.5 BATO 2024-08-16
O:VERV240816C00005000 OCASPS Call American 100 5 BATO 2024-08-16
O:VERV240816C00002500 OCASPS Call American 100 2.5 BATO 2024-08-16
O:VERV240719P00012500 OPASPS Put American 100 12.5 BATO 2024-07-19
O:VERV240719P00010000 OPASPS Put American 100 10 BATO 2024-07-19
O:VERV240719P00007500 OPASPS Put American 100 7.5 BATO 2024-07-19
O:VERV240719P00005000 OPASPS Put American 100 5 BATO 2024-07-19
O:VERV240719P00002500 OPASPS Put American 100 2.5 BATO 2024-07-19
O:VERV240719C00012500 OCASPS Call American 100 12.5 BATO 2024-07-19
O:VERV240719C00010000 OCASPS Call American 100 10 BATO 2024-07-19
O:VERV240719C00007500 OCASPS Call American 100 7.5 BATO 2024-07-19
O:VERV240719C00005000 OCASPS Call American 100 5 BATO 2024-07-19
O:VERV240719C00002500 OCASPS Call American 100 2.5 BATO 2024-07-19
O:VERV240621P00012500 OPASPS Put American 100 12.5 BATO 2024-06-21
O:VERV240621P00010000 OPASPS Put American 100 10 BATO 2024-06-21
O:VERV240621P00007500 OPASPS Put American 100 7.5 BATO 2024-06-21
O:VERV240621P00005000 OPASPS Put American 100 5 BATO 2024-06-21
O:VERV240621P00002500 OPASPS Put American 100 2.5 BATO 2024-06-21
O:VERV240621C00012500 OCASPS Call American 100 12.5 BATO 2024-06-21
O:VERV240621C00010000 OCASPS Call American 100 10 BATO 2024-06-21
O:VERV240621C00007500 OCASPS Call American 100 7.5 BATO 2024-06-21
O:VERV240621C00005000 OCASPS Call American 100 5 BATO 2024-06-21
O:VERV240621C00002500 OCASPS Call American 100 2.5 BATO 2024-06-21
O:VERV240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:VERV240517P00022500 OPASPS Put American 100 22.5 BATO 2024-05-17
O:VERV240517P00020000 OPASPS Put American 100 20 BATO 2024-05-17
O:VERV240517P00017500 OPASPS Put American 100 17.5 BATO 2024-05-17
O:VERV240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:VERV240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:VERV240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:VERV240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:VERV240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:VERV240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:VERV240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:VERV240517C00022500 OCASPS Call American 100 22.5 BATO 2024-05-17
O:VERV240517C00020000 OCASPS Call American 100 20 BATO 2024-05-17
O:VERV240517C00017500 OCASPS Call American 100 17.5 BATO 2024-05-17
O:VERV240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:VERV240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:VERV240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:VERV240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:VERV240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:VERV240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:VERV240517P00040000 OPASPS Put American 100 40 BATO 2024-05-17
O:VERV240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:VERV240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:VERV240517C00040000 OCASPS Call American 100 40 BATO 2024-05-17
O:VERV240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:VERV240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:VERV240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:VERV240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:VERV240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:VERV240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:VERV240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:VERV240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:VERV240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:VERV240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:VERV240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:VERV240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:VERV240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:VERV240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:VERV240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:VERV240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:VERV240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:VERV240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:VERV240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:VERV240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:VERV240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:VERV240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:VERV240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:VERV240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:VERV240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:VERV240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:VERV240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:VERV240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:VERV240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:VERV240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:VERV240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:VERV240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:VERV240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:VERV240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:VERV240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:VERV240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:VERV240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:VERV240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:VERV240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:VERV240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:VERV240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:VERV240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:VERV240216P00040000 OPASPS Put American 100 40 BATO 2024-02-16
O:VERV240216C00040000 OCASPS Call American 100 40 BATO 2024-02-16
O:VERV240216P00035000 OPASPS Put American 100 35 BATO 2024-02-16
O:VERV240216P00030000 OPASPS Put American 100 30 BATO 2024-02-16
O:VERV240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:VERV240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:VERV240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:VERV240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:VERV240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:VERV240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:VERV240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:VERV240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:VERV240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:VERV240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:VERV240216C00035000 OCASPS Call American 100 35 BATO 2024-02-16
O:VERV240216C00030000 OCASPS Call American 100 30 BATO 2024-02-16
O:VERV240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:VERV240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:VERV240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:VERV240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:VERV240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:VERV240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:VERV240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:VERV240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:VERV240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:VERV240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:VERV240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:VERV240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:VERV240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:VERV240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:VERV240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:VERV240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:VERV240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:VERV240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:VERV240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:VERV240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:VERV240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:VERV240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:VERV240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:VERV240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:VERV240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:VERV240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:VERV231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:VERV231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:VERV231215P00017500 OPASPS Put American 100 17.5 BATO 2023-12-15
O:VERV231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:VERV231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:VERV231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:VERV231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:VERV231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:VERV231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:VERV231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:VERV231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:VERV231215C00017500 OCASPS Call American 100 17.5 BATO 2023-12-15
O:VERV231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:VERV231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:VERV231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:VERV231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:VERV231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:VERV231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:VERV231117P00035000 OPASPS Put American 100 35 BATO 2023-11-17
O:VERV231117P00030000 OPASPS Put American 100 30 BATO 2023-11-17
O:VERV231117P00025000 OPASPS Put American 100 25 BATO 2023-11-17
O:VERV231117P00022500 OPASPS Put American 100 22.5 BATO 2023-11-17
O:VERV231117P00020000 OPASPS Put American 100 20 BATO 2023-11-17
O:VERV231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:VERV231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:VERV231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:VERV231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:VERV231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:VERV231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:VERV231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:VERV231117C00035000 OCASPS Call American 100 35 BATO 2023-11-17
O:VERV231117C00030000 OCASPS Call American 100 30 BATO 2023-11-17
O:VERV231117C00025000 OCASPS Call American 100 25 BATO 2023-11-17
O:VERV231117C00022500 OCASPS Call American 100 22.5 BATO 2023-11-17
O:VERV231117C00020000 OCASPS Call American 100 20 BATO 2023-11-17
O:VERV231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:VERV231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:VERV231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:VERV231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:VERV231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:VERV231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:VERV231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:VERV231020P00030000 OPASPS Put American 100 30 BATO 2023-10-20
O:VERV231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:VERV231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:VERV231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:VERV231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:VERV231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:VERV231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:VERV231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:VERV231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:VERV231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:VERV231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:VERV231020C00030000 OCASPS Call American 100 30 BATO 2023-10-20
O:VERV231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:VERV231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:VERV231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:VERV231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:VERV231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:VERV231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:VERV231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:VERV231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:VERV231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:VERV231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:VERV230915P00035000 OPASPS Put American 100 35 BATO 2023-09-15
O:VERV230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:VERV230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:VERV230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:VERV230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:VERV230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:VERV230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:VERV230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:VERV230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:VERV230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:VERV230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:VERV230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:VERV230915C00035000 OCASPS Call American 100 35 BATO 2023-09-15
O:VERV230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:VERV230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:VERV230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:VERV230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:VERV230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:VERV230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:VERV230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:VERV230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:VERV230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:VERV230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:VERV230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:VERV230818P00035000 OPASPS Put American 100 35 BATO 2023-08-18
O:VERV230818P00030000 OPASPS Put American 100 30 BATO 2023-08-18
O:VERV230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:VERV230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:VERV230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:VERV230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:VERV230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:VERV230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:VERV230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:VERV230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:VERV230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:VERV230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:VERV230818C00035000 OCASPS Call American 100 35 BATO 2023-08-18
O:VERV230818C00030000 OCASPS Call American 100 30 BATO 2023-08-18
O:VERV230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:VERV230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:VERV230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:VERV230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:VERV230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:VERV230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:VERV230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:VERV230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:VERV230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:VERV230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
Flux d'actualités
News Verve Therapeutics
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
Rosen Law Firm is encouraging investors of Verve Therapeutics, Inc. to seek legal counsel before the October 28, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that Verve Therapeutics made false and misleading statements about its VERVE-101 clinical trial and the potential benefits of its delivery system.
GlobeNewswire Inc. • Il y a 2 jours
News Verve Therapeutics
VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action
Verve Therapeutics, Inc. is facing a class action lawsuit alleging that the company misled investors about the circumstances under which its Heart-1 clinical trial would be halted and overstated the potential benefits of its proprietary LNP delivery system.
GlobeNewswire Inc. • Il y a 3 jours
News Verve Therapeutics
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Verve Therapeutics, Inc. (VERV) is facing a securities fraud lawsuit for allegedly making false and misleading statements about its Heart-1 Phase 1b clinical trial and the benefits of its proprietary lipid nanoparticle (LNP) delivery system.
Benzinga • Il y a 1 semaine
News Verve Therapeutics
Gainey McKenna & Egleston annonce qu'un recours collectif a été déposé contre Verve Therapeutics, Inc.
Un recours collectif en valeurs mobilières a été déposé contre Verve Therapeutics, Inc. (VERV) au nom des investisseurs qui ont acheté des titres de la société entre le 9 août 2022 et le 1er avril 2024. Le procès allègue que la société a fait des déclarations fausses et/ou trompeuses sur les circonstances dans lesquelles l'essai clinique de phase 1b Heart-1 de VERVE-101 serait interrompu, et a surestimé les avantages potentiels de son système d'administration de nanoparticules lipidiques (LNP) breveté.
GlobeNewswire Inc. • Il y a 1 semaine
Stocks Changes in company's own shares
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on June 28, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • Il y a 2 mois
Management Directors and Officers
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals. Ms. Morrison currently serves as chief executive officer and director of Q32 Bio Inc.
GlobeNewswire Inc. • Il y a 2 mois
Stocks Changes in company's own shares
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • Il y a 3 mois
Management Directors and Officers
Verve Therapeutics Announces Leadership Update
Troy Lister, Ph.D., to be promoted to chief scientific officer
GlobeNewswire Inc. • Il y a 3 mois
Investing investing
After a Serious Setback, Is Verve Therapeutics a Buy?
There are a few silver linings at play here.
The Motley Fool • Il y a 5 mois
Stocks Stock Market News
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on March 28, 2024, the company granted equity awards to six new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • Il y a 5 mois
Voir tous
Actualités liées
Dernières actualités

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT